News

What is happening in the Endpoint Outcomes world.

 

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Sunny Zhang as a Research Associate in our Long Beach office. Prior to joining Endpoint Outcomes, Sunny worked as an undergraduate research assistant in the Ong Lab developing microcarrier-based sensor technology for cell tracking. Additionally, he worked as a contact tracer at the University of Oregon to provide case management support for the local community. Sunny holds a Bachelor of Science degree in Biology with a minor in Biochemistry from the University of Oregon.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Ashley Willis, Blaise Cureg, Imani Weeks and Julia D’Ambrosio in our Boston office.

Prior to joining Endpoint Outcomes as a Research Associate, Ashley worked as an undergraduate research assistant in the Cancer Biology & Microchimerism Lab conducting cross-species analyses of the relationship between placental morphology and evolved cancer defenses and at the Center for Evolutionary Psychology developing and facilitating socio-behavioral experiments on reciprocal altruism. Ashley holds a Bachelor of Arts degree in Biological Anthropology & Sociology from the University of California, Santa Barbara.

Prior to joining Endpoint Outcomes as a Senior Research Associate, Blaise worked at Boston Medical Center, where she conducted qualitative community-based research for a project aimed at improving the mental health of the Black Church community. Blaise has also provided research support for studies examining alcohol policies and e-cigarette use. Blaise holds a Bachelor of Science degree in Psychology from the University of Vermont and a Master of Public Health Degree from Boston University.

Prior to joining Endpoint Outcomes as a Senior Research Coordinator, Imani worked as a clinical research coordinator for Center for Neurointestinal Health at Massachusetts General Hospital and supported research that focused on the intersection of eating disorders and gastrointestinal disorders. Imani has a Bachelor of Arts degree in Psychology from Harvard University.

Prior to joining Endpoint Outcomes as a Senior Research Associate, Julia interned as a research assistant with the Boston College School of Social Work, where she analyzed qualitative data on the diffusion and spillover effects of a mental health intervention done in Sierra Leone. Julia holds a Master in Public Health degree from Boston University, and a Bachelor of Arts degree in English from the College of the Holy Cross. 

Lumanity Acquires Endpoint Outcomes

Lumanity Acquires Endpoint Outcomes, Creating a Unique and Comprehensive Health Economics and Outcomes Research Offering

World-class outcomes research capability teamed with existing expertise in health economics puts the voice of patients at the center of drug development and value demonstration

New York, June 14, 2022 – Lumanity today announced the acquisition of Endpoint Outcomes (“Endpoint”), a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life.  The highly complementary acquisition of Endpoint Outcomes strengthens Lumanity’s value demonstration capabilities by creating a comprehensive, global health economics and outcomes research (“HEOR”) suite of services.

Chris Evans, CEO of Endpoint Outcomes, said, “We are excited to join Lumanity and proud to be part of a company with a purpose that aligns with our own.  We’ve built a great organization and believe that joining Lumanity is the next step in this journey, allowing us to continue to keep patients at the heart of everything we do.  With new colleagues and capabilities to tap into, we now have the ingredients to build ground-breaking solutions and drive even greater value for our clients and their patients.”

Endpoint Outcomes is a leader in the development and implementation of patient-centric clinical outcomes assessments (“COAs”).  Endpoint’s team of experts works with its clients to help define the value of new medical innovations and generate evidentiary support of the highest caliber for regulators, clinicians, payers, and patients.  The addition of Endpoint’s proven COA capability is critical to Lumanity’s mission of demonstrating the value of medical advances to optimize patient access, which requires the consideration and integration of economic, patient, and clinical outcomes.  The convergence of health economics and patient-centered outcomes research is necessary to support payer evaluations and health technology assessments for Lumanity’s most important clients.

Jon Williams, CEO of Lumanity, said, “We are thrilled to welcome Endpoint as party of Lumanity.  We were immediately impressed with the strength of the team, the quality of Chris’s leadership, and how well our views aligned on the strategic opportunities available to us as a combined force.  We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”

Lumanity was formed by bringing together the expertise and capabilities of several exceptional organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, and Innovative Edge.  The addition of Endpoint Outcomes further enhances Lumanity’s unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject matter experts, and proven problem solvers with advanced clinical, scientific, and functional capabilities.

CONTACT:
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com

About Lumanity

Lumanity applies incisive thinking and decisive action to cut through complex situations and deliver transformative outcomes to accelerate and optimize access to medical advances.  With deep experience in medical, commercial, and regulatory affairs, Lumanity transforms data and information into real-world insights and evidence that power successful commercialization and empower patients, providers, payers, and regulators to take timely and decisive action.

With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, Lumanity has 1,200+ experts working with top pharmaceutical and biotech companies to: identify and generate the evidence needed to demonstrate the value of their products and bring them to patients at a price reflective of that value; translate science and data into compelling product narratives that are relevant to stakeholders around the world; and, enable commercial decisions that position these products for sustainable success in the market.  Turning aspiration into reality, Lumanity helps to deliver successful development strategies, payer submissions, commercial brand launches, and product campaigns.

For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn

 

About Endpoint Outcomes

Endpoint Outcomes is a scientific research and consulting firm that specializes in incorporating the voice of patients in the drug development process to document the benefit of treatments on health-related quality of life and demonstrate the value of new medical innovations to regulatory bodies, clinicians, and patients.

Established in 2012 by Chris Evans, and with offices located in Boston, MA and Long Beach, CA, Endpoint Outcomes works with pharmaceutical and biotech companies to develop and validate outcome measures, prepare regulatory dossiers, provide regulatory consulting, develop endpoint strategies, conduct literature reviews and gap-analyses, and conduct eCOA equivalency testing.

For more information, please visit endpointoutcomes.com.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Somali Misra Burgess as a Vice President in our Long Beach office. Prior to joining Endpoint Outcomes, Somali was a Senior Research Scientist within the Patient-Centered Research team at Evidera. Other positions Somali has held include Senior Director and PRO Thought Leader at Xcenda; CEO and Research Director at Strategic Outcomes Services, a boutique consulting company that specialized in the development, validation, and evaluation of COAs and regulatory strategy; Vice President in the Endpoint Development and Outcomes Assessment group at Adelphi Values; and, Director in the GHEOR division at Allergan heading up the products/indications in Allergan Medical, Health, and Medical Dermatology. Somali has extensive experience developing and demonstrating value arguments for new and existing products/indications, COA evaluations, questionnaire development and validation, endpoint development, patient-centric research, and global regulatory strategies and submissions. Somali has a PhD in Pharmacoeconomics and Outcomes research from the College of Pharmacy, University of Georgia.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Grady Rojas as a Research Coordinator in our Long Beach office. Prior to joining Endpoint Outcomes, Grady worked as a safety specialist for a distribution center under their Environment, Health, and Safety department. Additionally, he has worked with UC Riverside School of Medicine to research how breast cancer disproportionately affects minority groups in the Inland Empire as part of a community health project. Grady holds a Bachelor’s of Science in Public Health and a minor in Ethnic Studies from the University of California, San Diego.

Recent Publications

Two manuscripts were recently published by staff at Endpoint Outcomes: the first is a manuscript that describes the development of the Activity Impairment in Migraine Diary (AIM-D) that was recently used to substantiate labeling claims with the FDA for a novel migraine treatment: Lipton RB, Ghandi P, Stokes J, Cala ML, Evans C, Knoble N, Gelhorn HL, Revecki D, Vishwanathan HN, Dodick DW.  Development and validation of a novel patient-reported outcome measure in people with episodic migraine: the Activity Impairment in Migraine.  Headache 2021; doi 10.1111/head.14229.

 

The second manuscript describes work carried out by Endpoint Outcomes to characterize the burden of a common eye condition on common daily tasks that require good near vision: Shimeshan E, Coon CD, Johnson N, Stokes J, Wells T, Lundy JJ, Andrae D, Evans CJ, Campbell J.  Development of the near vision presbyopia task-based questionnaire for use in evaluating the impact of presbyopia.  Journal of Patient-Reported Outcomes 2021; 5:125.

Clinical Outcome Assessments in Labeling

It is often a long and rigorous process to assist our clients with developing measures to support labeling claims.  Last week, two measures we developed were used to document treatment benefit from the perspective of patients for two of our sponsors and are captured in the product labels for atogepant and maralixibat.  The first, was the Activity Impairment in Migraine Diary (AIM-D) in the prevention of episodic migraine and the second was the Itch Reported Outcome Measure Observer Report [ItchRO (Obs)] in Alagille syndrome.  Many thanks to the researchers at Endpoint Outcomes for their hard work in putting the patient’s voice at the center of drug development.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Sophie Hill as a Research Associate in our Boston office. Prior to joining Endpoint Outcomes, Sophie worked as an undergraduate research assistant analyzing the impacts the medical device, Essure, had on individuals lives using data collected from the FDA’s MAUDE database. Sophie holds a Bachelor of Science degree in Public Health with a minor is Sociology from Simmons University.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Marc Bacharach as a Research Associate in our Boston office. Prior to joining Endpoint Outcomes, Marc worked as an undergraduate research assistant for Project HOPE, a preventative intervention study for maltreated infants. At Project HOPE, Marc transcribed interviews, conducted narrative coding of interview responses, and attended weekly consensus meetings. Additionally, Marc was selected for a one-year cognitive science research course in which he learned research methodologies and conducted a study on training methods to enhance visual acuity. Marc holds a Bachelor of Arts degree in Brain & Cognitive Sciences and Psychology with a minor in Philosophy from University of Rochester.

Welcome to Endpoint Outcomes

Endpoint Outcomes is pleased to welcome Kristi Van Meter as a Research Analyst in our Boston office. Prior to joining Endpoint Outcomes, Kristi interned at the Data Intensive Studies Center at Tufts University. Kristi also has a background in patient care, serving as a research assistant at the NeuroCognition Lab at Tufts and the Sleep, Cognition, and Neuropsychiatry Lab at Massachusetts General Hospital, an administrative coordinator at Massachusetts General Hospital, and a mental health specialist at McLean Hospital. Kristi graduated from Tufts University with a B.S. in Biopsychology and a minor in Philosophy.